SSBH 2025

Day 3 May 31(Sat) 09:00-10:10	Oral Presentation 3 Room 1

Chair(s): Dong Jin Chung (Chonnam National University, Korea), Hyuntae Park (Dong-A University, Korea)

Day 3 May 31(Sat) 10:15-11:05	Plenary Lecture 3 Room 1

Emerging evidence indicates that the cells of skeletal system demand large amount of energy for the development and function. The understanding of integrated mechanisms of energy metabolism and bone cells has been greatly enhanced by combined approaches using sophisticated modern analytical tools that enable the quantification of metabolic intermediates and advanced mouse genetic approaches that allow investigation into diverse molecular mechanisms. Dr. Thomas Clemens’ research is focused on the identification of cellular and molecular mechanisms by which osteoblast differentiation and activities are regulated and integrated with energy metabolism and homeostasis. In the current session, Dr. Clemens will discuss historical and contemporary studies that expands our knowledge of the metabolic properties of osteoblasts and their complex interactions with the metabolic and endocrine networks of the body. These novel insights will contribute to better understand the skeletal bioenergetics and its physiological significance in human health and diseases, especially in face of the increasing prevalence of diabetes and other metabolic disorders worldwide.

Chair(s): Deog Yoon Kim (Kyung Hee University, Korea)

10:15-11:05	Osteoblast Bioenergetics and Skeletal Energy Metabolism Thomas L. Clemens (University of Maryland, USA)

Day 3 May 31(Sat) 11:20-12:35	Symposium 4. Rare Bone Diseases: Unraveling Challenges and Advancing Solutions Room 1

Rare Bone Diseases (RBD) represent a particularly challenging area in diagnosis and treatment. Without timely detection and proper management, patients can endure significant suffering and long-term complications. This symposium will provide an in-depth exploration of the pathophysiology and advanced therapeutic approaches for RBDs, with distinguished experts from around the world sharing their insights and experiences. The first lecture, From Pathophysiology to Treatment: Burosumab in XLH Management, will delve into the pathophysiology of X-linked hypophosphatemia (XLH) and introduce the latest therapeutic strategies using Burosumab. The second lecture, Get Straight to the Source of Hypophosphatasia, will discuss the root causes of hypophosphatasia and share the latest treatment advancements targeting this condition. The final lecture, Rare Bone Diseases in Korea: Current Challenges and Future Directions, will analyze the challenges faced by patients with rare bone diseases in Korea and propose future solutions. Rare bone diseases have a profound impact on patients’ lives, yet they are often overlooked. This session aims to raise awareness of these conditions and provide valuable opportunities to improve the diagnosis and care of RBD patients.

Chair(s): Young-Joo Kwon (Korea University, Korea), Ha Young Kim (University of Ulsan, Korea)

11:20-11:45	New Horizons in XLH Management: Burosumab and Beyond Adalbert Raimann (Medical University of Vienna, Austria)
11:45-12:10	Get Straight to the Source of Hypophosphatasia Eric Rush (Children's Mercy Kansas City, USA)
12:10-12:35	Rare Bone Disease in Korea: Current Challenges and Future Directions Yumie Rhee (Yonsei University, Korea)

Day 3 May 31(Sat) 12:35-12:50	Luncheon Symposium 3 Room 1

Chair(s): Keeho Song (Konkuk University, Korea)

12:35-12:50	TBD TBD (TBD)

Day 3 May 31(Sat) 13:35-14:45	Oral Presentation 5 Room 1

Chair(s): Gun-Il Im (Dongguk University, Korea), Yoon-Kyoung Sung (Hanyang University, Korea)

Day 3 May 31(Sat) 15:00-16:15	Symposium 6. The Next Frontier in Bone Health: Exploring Anabolic Strategies Across Contexts Room 1

Anabolic therapies represent a groundbreaking paradigm in osteoporosis treatment by promoting bone formation, distinguishing themselves from traditional therapeutic approaches. This symposium will comprehensively explore the latest knowledge and clinical applications of anabolic therapies. The first lecture, Effects of Anabolics on Bone: Bridging the Gap Between Clinical Trials and Real-World Practice, will compare outcomes from clinical trials with real-world practice and discuss appropriate therapeutic strategies for effective implementation. The second lecture, Transforming Fracture Care: Paradigm Shifts with Anabolic Therapies, will focus on how anabolic therapies are driving paradigm shifts in fracture care, offering innovative approaches for treatment. The final lecture, Anabolics in Cancer Patients: To Use or Not to Use?, will analyze the potential benefits and risks of using anabolic therapies in cancer patients, exploring their feasibility in this unique population. This session aims to re-evaluate the potential of anabolic therapies and provide valuable insights into optimizing their use in clinical practice to achieve better patient outcomes.

Chair(s): Kyuri Hwang (Seoul National University, Korea), Seung-Hoon Baek (Kyungpook National University, Korea)

15:00-15:25	Effects of Anabolics on Bone: Bridging the Gap between Clinical Trials and Real-World Practice Ha Young Kim (University of Ulsan, Korea)
15:25-15:50	Transforming Fracture Care: Paradigm Shifts with Anabolic Therapies Jae Hyuk Yang (Korea University, Korea)
15:50-16:15	Anabolics in Cancer Patients: To Use or Not to Use? A Ram Hong (Chonnam National University, Korea)

Scientific Program